Currently recruiting in people newly diagnosed with type 1.

Testing TypeZero’s inControl artificial pancreas, six months at a time.

The 338-patient, Dexcom-sponsored DIaMonD Study aims to find out.

Currently enrolling! How does the pill form of this drug class compare to injected GLP-1s?

Intarcia just announced exciting results for ITCA 650 , a small implanted device to treat type 2 diabetes. The tiny device is implanted under the skin just once or twice...

Enrolling now – how this implanted CGM compares to current CGM offerings.

What are the implications for other injected GLP-1 agonist drugs?

Program designed for Medicaid and uninsured individuals at risk for diabetes. Omada Health recently announced the launch of Prevent for Underserved Populations. The new...

Enrolling at over 140 sites worldwide. Can it reduce A1c and insulin use and improve time-in-range?

Find nearby T1D, T2D, gestational diabetes, and complications trials with new clinical trials matching tool launched by JDRF and TrialReach

A six-month study of Diasome Pharmaceuticals’ HDV Insulin in Type 1 Diabetes

Recruiting participants in Boston at the Joslin Diabetes Center

Trial results testing sotagliflozin and Farxiga in type 1 diabetes show greater A1c lowering and weight loss, plus continued conversation about small risk of DKA

Seeking participants with type 2 diabetes to investigate the effects of semaglutide on heart health

Comparing Medtronic’s MiniMed 670G to injections and pumps in people with type 1 diabetes, with and without CGM; enrollment to open in May at some trial locations

A real-world trial in 3,000+ participants currently enrolling participants with type 2 diabetes

A six-week study of Tandem’s first automated insulin delivery device with Dexcom’s G5 CGM

A new study is investigating whether higher doses of injectable GLP-1 agonist Trulicity (dulaglutide) are more effective; it is recruiting 1,800 participants with type 2...

A new trial will test if the once-weekly injectable, Bydureon, is also safe and effective in adolescents.

Recruiting now! This major study will support FDA submission of Tandem’s t:slim X2 with Control-IQ and Dexcom G6 in people with type 1 ages 14 and up; includes automatic...